

**CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL (Large Entity)**

Submit an original, and a duplicate for fee processing.

(Only for Continuation or Divisional Applications Under 37 CFR 1.53(d))

Docket No.

BMID9967US

☒ **DUPLICATE** (Check box if applicable)

First Named Inventor

Examiner

Group/Art Unit

Hans-Georg JHLENFELDT, et al.

Rebecca E. PROUTY

1652

Address to:

Assistant Commissioner for Patents

Box CPA

Washington, D.C. 20231

This is a request for filing a ☒ continuation, or ☐ divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of application number 09/416,579 filed on October 12, 1999 and entitled:

DEOXYNUCLEOSIDE KINASE FROM INSECT CELLS FOR THE SYNTHESIS OF NUCLEOSIDE MONOPHOSPHATES

1. ☐ Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior nonprovisional application.
2. ☐ A preliminary amendment is enclosed.
3. ☐ This application is being filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
- a. ☐ **DELETE** the following inventor(s) named in the prior nonprovisional application:
- b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. ☒ A new power of attorney or authorization of agent is enclosed.
5. ☐ An Information Disclosure Statement (IDS) is enclosed:
- a. ☐ PTO-1449
- b. ☐ Copies of IDS Citations
6. ☒ The fee for this application is calculated as follows:

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	7	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	1	- 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$740.00
TOTAL FILING FEE					\$740.00

05/24/2002 RWD:DAF1 00000110 500077 09416579

01 TC:131 740.00 CH

RECEIVED

MAY 24 2002

TECH CENTER 1600/2900

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity)
(Only for Continuation or Divisional Applications Under 37 CFR 1.53(d))

7. ☒ The Commissioner is hereby authorized to credit overpayments or charge the following fees to
Deposit Account No. 50-0877

- ☒ fees required under 37 C.F.R. 1.16.
- ☒ fees required under 37 C.F.R. 1.17.
- ☐ fees required under 37 C.F.R. 1.18.

8. ☐ A check in the amount of _____ is enclosed.


9. ☒ Also enclosed:
Petition for Extension of Time Under 37 CFR 1.136(a) (1pg) in duplicate, General Appointment of Representative for
U.S. Patent and Trademark Office Matter (1pg), and return postcard



10. ☒ The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below:

Kenneth J. Waite, Reg. No. 45,189
Roche Diagnostics Corporation
9115 Hague Road, Bldg D
P.O. Box 50457
Indianapolis, IN 46250-0457

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity)
(Only for Continuation or Divisional Applications Under 37 CFR 1.53(d))



NOTES

Submit an original, and a duplicate for fee processing.

FILING QUALIFICATIONS: The prior application must be a nonprovisional application that is either: (1) complete as defined by 37 C.F.R. 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 USC 154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.


C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 C.F.R. 1.53(d), but must be filed under 37 C.F.R. 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 C.F.R. 1.53(b) must be used to file a continuation, divisional or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the Applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 C.F.R. 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or application in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 C.F.R. 1.78(a).

Dated: May 21, 2002


Signature

Kenneth J. Waite

Typed or printed name

45,189

Registration Number (if applicable)

- ☐ Inventor(s)
☐ Assignee of complete interest
☒ Attorney or agent of record

CC:

MAY 24 2002

RECEIVED

TECH CENTER 1600



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, DC 20231


**GENERAL APPOINTMENT OF REPRESENTATIVE FOR
U.S. PATENT AND TRADEMARK OFFICE MATTERS**

The undersigned applicant or assignee hereby appoints D. Michael Young, Reg. No. 33,819, Brent A. Harris, Reg. No. 39,215, Richard T. Knauer, Reg. No. 35,575, Kenneth J. Waite, Reg. No. 45,189, Marilyn L. Amick, Reg. No. 30,444, and Michelle Neff, Reg. No. 47,817, all of Roche Diagnostics Corporation, 9115 Hague Road, P.O. Box 50457, Indianapolis, Indiana 46250, Telephone No. (317) 845-2000, and Jill Lynn Woodburn, Reg. No. 39,874 of The Law Office of Jill L. Woodburn, L.L.C., 6633 Old Stonehouse Drive, Newburgh, Indiana 47630-1785, Telephone No. (812) 842-2660:

to prosecute and transact all business on its behalf before the United States Patent and Trademark Office in connection with any U.S. patent assigned to it and any U.S. patent application filed by it or on its behalf and to receive payments on its behalf.

Signed this 11th day of April, 2001 at Mannheim, Germany.

Roche Diagnostics GmbH


Signature


Dr. Michael Jung

Print Name

Senior Director

Position or Title

Roche Diagnostics GmbH


Signature

Dr. Anton Silber

Print Name

Director

Position or Title

05-23-02

CPA 11660 \$

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Applicant(s): Hans-Georg IHLENFELDT, et al.			Docket No. BMID9967US
Serial No. 09/416,579	Filing Date October 12, 1999	Examiner Rebecca E. Prouty	Group Art Unit 1652

Invention: DEOXYNUCLEOSIDE KINASE FROM INSECT CELLS FOR THE SYNTHESIS OF NUCLEOSIDE MONOPHOSPHATES



RECEIVED
MAY 24 2002
TECH CENTER 1600/2900

I hereby certify that this Continued Prosecution Application (CPA)
(Identify type of correspondence)
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under
37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.
20231-0001 on May 21, 2002
(Date)

MICHELE WILSON
(Typed or Printed Name of Person Mailing Correspondence)
Michelle Wilson
(Signature of Person Mailing Correspondence)
EL841987090US
(Express Mail Mailing Label Number)

Note: Each paper must have its own certificate of mailing.